Appraisal_NN
of_IN
potential_JJ
therapeutic_JJ
index_NN
of_IN
antioxidants_NNS
on_IN
the_DT
basis_NN
of_IN
their_PRP$
in_FW
vitro_FW
effects_NNS
on_IN
HIV_NN
replication_NN
in_IN
monocytes_NNS
and_CC
interleukin_NN
2-induced_JJ
lymphocyte_NN
proliferation_NN
._.

Antioxidant_JJ
molecules_NNS
have_VBP
been_VBN
suggested_VBN
to_TO
be_VB
of_IN
therapeutic_JJ
value_NN
in_IN
the_DT
treatment_NN
of_IN
HIV-infected_JJ
patients_NNS
._.

To_TO
evaluate_VB
this_DT
possibility_NN
,_,
we_PRP
examined_VBD
in_FW
vitro_FW
the_DT
effects_NNS
of_IN
two_CD
types_NNS
of_IN
antioxidant_JJ
molecules_NNS
in_IN
terms_NNS
of_IN
inhibition_NN
of_IN
HIV_NN
replication_NN
in_IN
monocytes_NNS
,_,
one_CD
of_IN
the_DT
main_JJ
reservoirs_NNS
of_IN
HIV_NN
,_,
and_CC
also_RB
in_IN
terms_NNS
of_IN
modulation_NN
of_IN
the_DT
immune_JJ
competence_NN
as_IN
measured_VBN
by_IN
PBMC_NN
proliferation_NN
._.

We_PRP
tested_VBD
the_DT
effects_NNS
of_IN
BHA_NN
,_,
a_DT
phenolic_JJ
,_,
lipid-soluble_JJ
,_,
chain-breaking_JJ
antioxidant_NN
,_,
and_CC
NAC_NN
,_,
a_DT
known_JJ
glutathione_NN
precursor_NN
with_IN
some_DT
direct_JJ
free-radical_JJ
scavenging_NN
properties_NNS
as_RB
well_RB
,_,
on_IN
the_DT
regulation_NN
of_IN
HIV-1_NN
expression_NN
in_IN
latently_RB
infected_VBN
U1_NN
cells_NNS
and_CC
in_IN
productively_RB
and_CC
chronically_RB
infected_VBN
U937_NN
cells_NNS
._.

Both_DT
antioxidants_NNS
inhibited_VBD
TNF_NN
-_:
or_CC
PMA-induced_JJ
NF-kappa_NN
B_NN
activity_NN
in_IN
U1_NN
cells_NNS
,_,
as_RB
well_RB
as_IN
the_DT
sustained_JJ
NF-kappa_NN
B_NN
activity_NN
permanently_RB
induced_VBN
by_IN
the_DT
virus_NN
itself_PRP
in_IN
chronically_RB
HIV-infected_JJ
U937_NN
cells_NNS
._.

This_DT
resulted_VBD
in_IN
only_RB
a_DT
partial_JJ
inhibition_NN
of_IN
TNF_NN
-_:
or_CC
PMA-induced_JJ
HIV_NN
replication_NN
in_IN
U1_NN
cells_NNS
,_,
and_CC
no_DT
detectable_JJ
effect_NN
on_IN
HIV_NN
replication_NN
in_IN
chronically_RB
infected_VBN
U937_NN
cells_NNS
._.

This_DT
may_MD
be_VB
the_DT
first_JJ
limitation_NN
to_TO
potential_JJ
antiviral_JJ
effects_NNS
of_IN
antioxidant_JJ
therapies_NNS
._.

Another_DT
limitation_NN
is_VBZ
that_IN
antioxidant_JJ
concentrations_NNS
high_JJ
enough_RB
to_TO
block_VB
NK-kappa_NN
B_NN
activation_NN
were_VBD
shown_VBN
to_TO
have_VB
a_DT
suppressive_JJ
effect_NN
on_IN
immune_JJ
functions_NNS
in_FW
vitro_FW
,_,
because_IN
NAC_NN
and_CC
BHA_NN
blocked_VBD
IL-2-induced_JJ
PBMC_NN
proliferation_NN
._.

These_DT
data_NNS
warrant_VBP
prudence_NN
in_IN
the_DT
design_NN
of_IN
antioxidant-based_JJ
therapies_NNS
aimed_VBN
at_IN
suppressing_VBG
HIV_NN
replication_NN
._.

